AHA: 20 late-breaking trials, 19 special reports on docket

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
 - Dallas

The American Heart Association (AHA) will present 20 late-breaking clinical trials and 20 clinical science-special reports at its scientific sessions in Dallas. The conference runs Nov. 16-20.

Here is the schedule for late-breaking trials:

Sunday, Nov. 17

  • Nitrites in Acute Myocardial Infarction
  • Blood Pressure Reduction Among Acute Ischemic Stroke Patients: A Randomized Controlled Clinical Trial
  • Randomized Clinical Trial of Pre-hospital Induction of Mild Hypothermia in Out-of-Hospital Cardiac Arrest Patients Using a Rapid Infusion of 4oC Normal Saline
  • Target Temperature Management 33°C versus 36°C after Out-of-hospital Cardiac Arrest, a Randomized, Parallel Group, Assessor Blinded Clinical Trial

Monday, Nov. 18

  • Promotion of Cardiovascular Health in Preschool Children: 36-month Cohort Follow-up
  • Randomized Trial of Social Network Lifestyle Intervention for Obesity: MICROCLINIC Intervention Results and 16-Month Follow-up
  • Multifaceted Intervention to Improve Medication Adherence and Secondary Prevention Measures (Medication Study) After Acute Coronary Syndrome Hospital Discharge
  • China Rural Health Initiative - Sodium Reduction Study: the Effects of a Community-Based Sodium Reduction Program on 24hr Urinary Sodium and Blood Pressure in Rural China
  • Atrial Antitachycardia Pacing and Managed Ventricular Pacing Reduce the Endpoint Composed by Death, Cardiovascular Hospitalizations and Permanent Atrial Fibrillation Compared to Conventional Dual Chamber Pacing in Bradycardia Patients: Results of the Minerva Randomized Study
  • Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) Trial
  • Severe Ischemic Mitral Regurgitation: Is it Better to Repair or Replace the Valve?
  • Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT)
  • One Year Mortality in STEMI Patients Randomized to Primary PCI or a Pharmaco-invasive Strategy. The Stream 1 Year Follow-up
  • Secretory Phospholipase A2 Inhibition with Varespladib and Cardiovascular Events in Patients with an Acute Coronary Syndrome: Results of the VISTA-16 Study
  • Randomized Comparison of Endovascular Revascularization Plus Supervised Exercise Therapy Versus Supervised Exercise Therapy Only in Patients With Peripheral Artery Disease and Intermittent Claudication: Results of the Endovascular Revascularization and Supervised Exercise (ERASE) Trial
  • A Randomized Multicenter Clinical Trial of Renal Artery Stenting in Preventing Cardiovascular and Renal Events: Results of the CORAL Study

Tuesday, Nov. 19

  • RADAR-AF Trial. A Randomized Multicenter Comparison of Radiofrequency Catheter Ablation of Drivers versus Circumferential Pulmonary Vein Isolation in Patients with Atrial Fibrillation
  • A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Warfarin Study
  • The Clarification of Optimal Anticoagulation through Genetics (COAG) Trial
  • ENGAGE AF-TIMI 48 Primary Results

Here is the schedule for the clinical science/special reports:

Monday, Nov. 18

  • State of the Art: Cardiac Stem Cell Therapeutics from the Outside, Looking In
  • Mechanisms of Bone Marrow Derived Cell Therapy in Ischemic Cardiomyopathy with Left Ventricular Assist Device (LVAD) Bridge to Transplant
  • Assessment of Safety and Efficacy of Autologous Mesenchymal Stem Cells and Whole Bone Marrow in Patients with Ischemic Cardiomyopathy: The TAC-HFT Trial
  • Intramyocardial Injection of Allogeneic Mesenchymal Precursor Cells in Left Ventricular Assist Device Patients
  • The NHLBI TIME Trial: One-Year Results
  • Safety And Efficacy Of Sitagliptin Plus Granulocyte-colony Stimulating Factor In Patients Suffering From Acute Myocardial Infarction - Sitagrami Trial
  • Effect of Progenitor Cell Mobilization with Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Patients with Peripheral Artery Disease and Claudication; GPAD-II: A Phase II Randomized Study

Tuesday, Nov. 19

  • Outcome Impact of Coronary Revascularization Strategy - Reclassification With Fractional Flow Reserve (FFR) at time of diagnostic angiography: Insights from a Large French Multicenter FFR Registry (R3F)
  • CPT1A Methylation is a Novel Epigenetic Marker of Cardiovascular Risk
  • Ten-Year Incidence Rates of Major Cardiovascular Events in 697,690 Immigrants to Ontario, Canada, by Ethnic Group and Country of Birth
  • China Rural Health Initiative - Primary Care Provider Study: A Large Cluster-Randomized Controlled Trial of High Cardiovascular Risk Management in Rural China
  • Does Aspirin Intake at Bedtime Decrease Blood Pressure and Morning Peak of Platelet Reactivity?: A Randomized Cross-over Trial
  • Daylight: Vitamin D Therapy in Individuals at High Risk of Hypertension
  • Effect of Angiotensin II Type I Receptor Blockade on Carotid Artery Atherosclerosis: A Randomized Trial Comparing Valsartan and Placebo (EFFERVESCENT)
  • Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145 versus Standard of Care in 1104 Patients: 52-week Results from the OSLER Study

Wednesday, Nov. 20

  • The Incidence of Kidney Injury for Patients Treated with Intensive versus Less Potent Statin Therapy after an Acute Coronary Syndrome
  • First-in-Man Clinical Evaluation of a Novel Tissue Engineered Vascular Graft
  • Dedicated ICD Programming Reduces the Number of Inappropriate Therapies in a Real World Primary Prevention ICD Population: The DECREASE – Trial
  • A Multicenter, Randomized Study Assessing the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Advanced Heart Failure Patients with Ischemic and Non-ischemic Cardiomyopathy: Interim Results of the AUGMENT-HF Study